Heron Therapeutics (NASDAQ:HRTX) Q2 Earnings Miss: What’s Next for the Pharmaceutical Stock?
- Heron Therapeutics reported a Q2 loss per share of -$0.03, missing analyst expectations of about -$0.02.
- The company’s quarterly revenue of $37.67 million fell short of expectations of approximately $42.19 million, a miss of about 10.7%.
- In response to slower product expansion and increased competition, Heron paused its planned salesforce expansion and withdrew its full-year financial outlook.
Heron Therapeutics (NASDAQ:HRTX) is a pharmaceutical company focused on acute care and oncology-supportive care products. Its main products include ZYNRELEF for postoperative pain, APONVIE for postoperative nausea and vomiting, and CINVANTI for chemotherapy-induced nausea and vomiting.
On August 10, 2026, Heron Therapeutics announced its second-quarter earnings. The company reported a loss per share of -$0.03, compared with analyst expectations of around -$0.02. This was also a wider loss than the -$0.02 per share reported in the same quarter last year.
The company’s revenue for the quarter was $37.67 million, below the estimated $42.19 million. This represents a revenue miss of about 10.7%. However, revenue was slightly higher than the $37.2 million reported in the second quarter of the previous year.
Despite 44% year-over-year growth in its acute-care franchise, management noted that expansion of ZYNRELEF and APONVIE was slower than planned. CINVANTI sales also declined from the prior year due to branded competition, even though the product showed some sequential improvement.
In response to these results and the recent CINVANTI patent decision, Heron paused its planned salesforce expansion and withdrew its full-year financial outlook. The company remains unprofitable, reflected by its negative P/E ratio, while its high debt-to-equity ratio points to elevated financial risk.
